More than 31 million Americans are living with eczema/ atopic dermatitis (AD), a chronic inflammatory skin condition that extends far beyond visible symptoms to disrupt sleep, mental health, and daily ...

Positive results were announced from a phase 3 trial evaluating the efficacy and safety of dupilumab in children aged 6 months to 5 years with moderate to severe atopic dermatitis. The randomized, ...

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action ...

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

SILVERBERG: As a board-certified dermatologist in an academic referral center, I encounter a substantial caseload of patients with atopic dermatitis and other chronic inflammatory skin conditions.

Atopic dermatitis, the most common form of eczema, is a widespread skin condition known for causing dry, itchy and inflamed skin. It affects 15% to 20% of children and 8% to 10% of adults. The ...

Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with about 60% of cases starting before age 1.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Please provide your email address to receive an email when new articles are posted on . A study explored patch test results of dupilumab in atopic dermatitis. The use of dupilumab did not greatly ...

This article was originally published in French on Medscape. PARIS — The 17th Congrès Francophone d'allergologie (CFA), a congress of French-speaking allergists, took place April 19-April 22 at the ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.